Ayala Pharmaceuticals, Inc,

Quick facts

Phase 2 pipeline

• AL101 · Oncology
  AL101 is an inhibitor of the PI3K/AKT/mTOR pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ayala Pharmaceuticals, Inc, portfolio CI brief
• Ayala Pharmaceuticals, Inc, pipeline updates RSS